The “Meet Mark” Campaign Strategy
The pharmaceutical lobby has intensified its opposition to nonprofit health systems’ expanding use of the 340B Drug Discount program through a sophisticated advertising campaign. The Pharmaceutical Research and Manufacturers of…
The ICH E9(R1) Addendum on Estimands and Sensitivity Analysis provides a framework for defining the treatment effect a trial intends to estimate—the estimand. The addendum is widely adopted in pharmaceutical research. However, it remains…
Continue Reading
What You Should Know:
– The pharmaceutical research and development (R&D) sector is experiencing a significant upswing, with projected returns on investment climbing to 5.9% in 2024, according to a new report by Deloitte.
– This…
Continue Reading
Revolutionary Phase III Trial Results
Bayer has announced groundbreaking topline results from their Phase III QUANTI studies evaluating gadoquatrane, an innovative gadolinium-based contrast agent (GBCA) for magnetic resonance imaging (MRI). The revolutionary aspect of this…
